3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
18
Genitourinary
6
CNS
6
Breast
6
Other hematologic neoplasm
5
Lymphoid
5
Sarcoma
4
Plasma cell
4
Myeloid
4
Dermatologic
4
Head & Neck
2
Gastrointestinal
2
Endocrine
2
Thoracic
1
NET
1
Conditions
Neuroendocrine Tumors
169
Carcinoid Tumor
27
Carcinoma, Neuroendocrine
22
Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
16
Adenoma, Islet Cell
15
Pancreatic Neoplasms
12
Neoplasm Metastasis
10
Pheochromocytoma
8
Paraganglioma
8
Sarcoma
7
Colorectal Neoplasms
7
Carcinoma
7
Neuroectodermal Tumors, Primitive
6
Neuroblastoma
6
Gastrointestinal Neoplasms
6
Vipoma
5
Somatostatinoma
5
Gastrinoma
5
Cholangiocarcinoma
5
Carcinoma, Islet Cell
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Digestive System Neoplasms
4
Anus Neoplasms
4
Thyroid Neoplasms
3
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Interventions
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Gestational Trophoblastic Disease
×
NET
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled